Anesthesia

"patient-controlled analgesia (PCA) — standard parameters, opioid selection and safety features [4]. Outline a multimodal analgesic strategy for major abdominal surgery [3]. ⚙ Core Concept Acute postoperative pain is undertreated in 50% of surgical patients — with consequences including immobility, atelectasis, DVT, poor wound healing, and progression to chronic post-surgical pain (CPSP). A multimodal approach (combining analgesics with different mechanisms to achieve additive/synergistic analgesia with reduced individual drug doses and side effects) is the evidence-based standard. (WHO analgesic ladder 1986; Kehlet H — multimodal analgesia; PROSPECT guidelines; Rawal N — PCA pharmacology) A. WHO Analgesic Ladder — Application to Acute Pain 3 marks WHO ladder (1986) — originally for cancer pain, now adapted for acute postoperative pain: Step 1 (mild pain — VAS 1–3/10): non-opioid analgesics — paracetamol (1g QDS IV or oral) ± NSAIDs/COX-2 inhibitors (ibuprofen 400 mg TDS, diclofenac 75 mg BD, celecoxib 200 mg BD — contraindicated in: renal impairment, peptic ulcer disease, cardiovascular disease, post-GI surgery, pregnancy >30 weeks) Step 2 (moderate pain — VAS 4–6/10): weak opioid ± non-opioid — codeine 30–60 mg 4-hourly (hepatically metabolised to morphine via CYP2D6 — ultra-rapid metabolisers [10% of Caucasians] → toxic morphine levels; poor metabolisers → no analgesia; therefore codeine is unpredictable; tramadol 50–100 mg QDS — dual mechanism: weak μ agonist + SNRI; serotonin syndrome risk with SSRIs/MAOIs) Step 3 (severe pain — VAS 7–10/10): strong opioid ± non-opioid ± adjuvants — morphine, oxycodone, fentanyl, hydromorphone; PCA (see below); IV patient-titrated loading boluses (titrate 2–5 mg morphine IV every 5 min until VAS ≤3) Adaptation for acute postoperative pain: the WHO ladder is used in REVERSE for acute pain (Step 3 first, then stepping DOWN as pain improves) — this is the ""reverse ladder"" concept; pre-operatively: anticipate pain intensity and plan multimodal strategy rather than reacting to pain after it occurs (pro-active vs reactive analgesia) Adjuvants at any step: gabapentinoids (pregabalin 150 mg BD, gabapentin 300 mg TDS — ↓ central sensitisation, ↓ opioid requirements, ↓ PONV; most useful in neuropathic or chronic pain component); ketamine sub-anaesthetic infusion (0.1–0.2 mg/kg/h — NMDA antagonist, prevents central sensitisation, reduces opioid requirements); α₂ agonists (clonidine, dexmedetomidine — spinal and systemic analgesia) B. Patient-Controlled Analgesia (PCA) Pharmacology 4 marks PCA rationale: analgesic requirements vary 5-fold between patients of the same weight undergoing the same procedure (due to genetic variability in opioid metabolism, receptor sensitivity, pain threshold, anxiety, pre-operative opioid tolerance); a fixed-dose nurse-administered schedule cannot accommodate this variability; PCA allows the patient to self-administer small boluses when pain exceeds their individual threshold → rapid titration to individual analgesic requirement Standard PCA parameters (morphine IV): Parameter Standard Value (Morphine) Rationale Bolus dose 1 mg morphine (range 0.5– 2.5 mg) Small enough that a single extra dose does not cause respiratory depression; large enough to provide meaningful analgesia; in elderly >70: 0.5–1 mg; opioid-tolerant patients may need 2–2.5 mg Lockout interval 5 minutes Time to peak effect of IV morphine (5–10 min); prevents stacking before previous dose has taken effect; shorter lockout → ↑ overdose risk; longer → ↑ inadequate analgesia Background (continuous) infusion NOT routinely recommended (0 mg/h) Background infusion → ↑ opioid accumulation during sleep → ↑ respiratory depression risk (ISMP warning); reserved for opioid- tolerant patients (chronic opioid users) — match their baseline opioid requirements as background; children PCA-by-proxy: nurse or parent presses button → ↑ risk of overdose — NOT safe without HCA (healthcare professional-activated) 1-hour limit (or 4-hour limit) 10–20 mg/h (cumulative safety limit) Prevents excessive cumulative dosing; alerts nursing staff to reassess patient Concentration Morphine 1 mg/mL Standard concentration; errors occur with non-standard concentrations Opioid selection for PCA: Morphine — standard; active metabolite morphine-6-glucuronide (M6G) accumulates in renal failure → prolonged sedation; hydrophilic → slower onset (10–15 min) → higher bolus requirements Fentanyl — lipophilic → faster onset (5–7 min) → better titration; no active metabolites; preferred in renal failure; bolus 20–25 mcg (lockout 5 min) Oxycodone — intermediate lipophilicity; active metabolite oxymorphone; oral bioavailability 60–87% → oral oxycodone PCA available in some centres Hydromorphone — 5–7× more potent than morphine; active 3-glucuronide metabolite (accumulates in renal failure); bolus 0.2–0.4 mg PCA safety features: anti-reflux one-way valve (prevents siphoning of opioid into IV fluid bag); anti-tamper device; programmable lockout (cannot override); nurse override key (for loading dose); alarmed when reservoir low; dedicated PCA IV line (do NOT co-infuse other IV drugs — bolus of flush pushes PCA opioid → inadvertent overdose); monitoring: sedation score (Ramsay or RASS) + RR + SpO₂ (continuous overnight in high-risk patients) C. Multimodal Analgesic Strategy — Major Abdominal Surgery 3 marks Timing Intervention Rationale Pre-operative Celecoxib 400 mg PO + gabapentin 600 mg PO (pre-emptive analgesia); patient education and expectations; mark and plan regional technique; consent for epidural or TAP block Pre-emptive analgesia: giving analgesics before surgical injury → prevents central sensitisation before it occurs (more effective than treating established sensitisation post-op) Intraoperative Thoracic epidural (T6–T9 for upper abdominal; T9–T12 for lower) + TIVA propofol-remifentanil OR LA wound infiltration/TAP block at end; IV paracetamol 1g at induction; IV ketorolac 15–30 mg at wound closure; sub-anaesthetic ketamine 0.3 mg/kg/h infusion during surgery; dexamethasone 8 mg at induction (PONV + reduces pain); tranexamic acid (if applicable — ↓ blood loss) Epidural provides best post-op analgesia for open abdominal surgery; TAP block for laparoscopic; ketamine infusion → reduces opioid consumption 25–40% and PONV Postoperative Epidural infusion (bupivacaine 0.1% + fentanyl 2 mcg/mL) at 6–12 mL/h (if epidural in situ) OR PCA morphine/oxycodone (if no epidural); regular paracetamol 1g QDS; regular celecoxib 200 mg BD (if no contraindication — avoid in anastomotic bowel surgery — anastomotic leak risk); gabapentin 300 mg BD; breakthrough: oramorph 5–10 mg oral or morphine 2.5 mg IV; VAS assessment 4-hourly Regular non-opioid base → reduces opioid requirements 20–40%; epidural significantly reduces pulmonary complications, ileus, and hospital stay in open abdominal surgery (Kehlet 1999) ★ Examiner's Pearl WHO ladder adapted for acute pain: use in REVERSE (Step 3 first → step down). PCA standard: morphine 1 mg bolus, 5 min lockout, NO routine background infusion (↑ respiratory depression risk during sleep). Renal failure: avoid morphine (M6G accumulation) → use fentanyl. Multimodal strategy for major abdominal: epidural (best for open) + paracetamol + NSAID/COX-2 + gabapentin + ketamine infusion + dexamethasone = reduces opioid requirements 40–50%. Pre-emptive analgesia: given BEFORE surgical injury → prevents central sensitisation. References: Kehlet H, Dahl JB. The value of ""multimodal"" or ""balanced analgesia"" in postoperative pain treatment (Anesth Analg 1993;77:1048-1056). Macintyre PE. Safety and efficacy of patient-controlled analgesia (Br J Anaesth 2001;87:36-46). WHO. Cancer Pain Relief, 1986. Miller RD et al. Miller's Anaesthesia, 9th Ed, Chapter 64."

"anaesthetic drug properties for ECT and comparison of induction agents [4] (c) Special considerations and contraindications in ECT [2]. A. Physiological Responses to ECT 4 marks ⚙ Core Concept ECT delivers a brief electrical stimulus to the brain to induce a generalised seizure — the therapeutic agent is the seizure itself (not the electrical stimulus). The anaesthetic challenge is to: (1) provide rapid onset unconsciousness and profound amnesia; (2) provide adequate muscle relaxation (to prevent orthopaedic injury from convulsions) without suppressing the seizure; (3) manage significant autonomic haemodynamic swings; (4) allow rapid recovery for outpatient/day-case scheduling. (Fink M — ECT pharmacology; NICE guidelines ECT; Miller's Anaesthesia 9th Ed) Phase Physiological Response Mechanism Clinical Significance / Management Immediately pre-stimulus (vagal phase) Brief parasympathetic response: ↓ HR, brief asystole (seconds), ↓ BP Cortical activation of vagal nuclei before generalised seizure Transient — usually self-limiting in seconds; atropine 0.3–0.6 mg IV (or IM 30 min before) if significant bradycardia historically; now some centres use glycopyrrolate pre-medication; continuous ECG monitoring essential During seizure (sympathetic phase) Massive sympathetic surge: ↑↑ HR (tachycardia 25–30%), ↑↑ BP (MAP ↑ 30–50%), ↑ cerebral blood flow, ↑ ICP, ↑ intraocular pressure, ↑ intragastric pressure; arrhythmias (PVCs, SVT) Generalised tonic-clonic seizure → massive central sympathetic discharge + catecholamine release (adrenaline ↑ 5–15× above baseline) The haemodynamic surge is the most significant risk — in patients with IHD, aortic aneurysm, or recent MI, the surge can trigger ischaemia or dissection; β-blockers (esmolol 1–2 mg/kg IV 2 min before stimulus OR metoprolol 1–2 mg IV) effectively blunt the haemodynamic response without compromising seizure quality; esmolol preferred (ultra-short-acting β₁ blocker — does not prolong stimulus block duration) Post-ictal phase Parasympathetic rebound: bradycardia, ↓ BP; then recovery; may have transient confusion, agitation, headache, myalgia, ↑ PONV; post-ictal apnoea (1–2 min) → maintain oxygenation by bag- mask ventilation Post-seizure cortical inhibition; parasympathetic rebound Maintain airway support; O₂ supplementation; anti-emetics pre-medication (ondansetron); PONV prophylaxis important (frequent treatments — up to 3× per week); headache: paracetamol; agitation: midazolam 1–2 mg IV; recovery area monitoring minimum 30 min Cerebral effects ↑ CMRO₂ during seizure (↑ 3–5×); ↑ CBF (CMRO₂-coupled); ↑ ICP; ↑ BBB permeability; post-ictally: ↓ CMRO₂ (post-ictal suppression on EEG) Generalised cortical neuronal firing → massive ↑ O₂ demand → CBF ↑ to match; ICP elevation during seizure is transient and usually well- tolerated by patients with normal ICP Raised ICP = RELATIVE contraindication (see below); ↑ glucose (stress response + sympathetic activation → glycogenolysis); monitor BGL in diabetic patients B. Ideal ECT Anaesthetic Agent Properties and Comparison 4 marks Ideal properties of induction agent for ECT: rapid onset (for amnesia and comfort); rapid recovery (ECT done 2–3× weekly in outpatients — rapid return to baseline); minimal anticonvulsant effect (must not suppress the therapeutic seizure — seizure duration target ≥20–25 seconds; EEG seizure duration target ≥25 seconds); minimal cardiovascular depression; antiemetic properties (PONV frequent in ECT); amnesic; no myalgia Agent Anticonvulsant Effect Recovery ECT Suitability Methohexitone (methohexital) — gold standard where available Minimal anticonvulsant effect (LOWEST of all barbiturates at ECT doses); may have mild proconvulsant effect (epileptiform activity on EEG) Rapid (shorter duration than thiopentone) PREFERRED agent for ECT; seizure duration consistently longest with methohexitone; 1–1.5 mg/kg; pain on injection; not widely available in all countries (supply issues) Propofol SIGNIFICANT anticonvulsant effect — consistently reduces seizure duration by 30– 50% compared to methohexitone; ↑ seizure threshold; higher stimulation required Excellent rapid recovery; antiemetic; preferred for PONV-prone patients Second-line (or preferred in some centres for PONV); acceptable if ECT team adjusts stimulus energy upward to compensate; avoid if very short ictal duration is a persistent problem Thiopentone Anticonvulsant (more than methohexitone, less than propofol) Moderate (hangover) Acceptable alternative when methohexitone unavailable; longer recovery than propofol Etomidate Minimal anticonvulsant effect; may ↑ seizure duration Rapid Used when prolonging seizure duration is desirable (prior short seizures with propofol); significant myoclonus on induction (alarm/distress patient); adrenocortical suppression limits frequent use (ECT 3×/week → cumulative adrenal suppression) Ketamine No significant anticonvulsant effect; mild Moderate Not generally preferred; ↑ BP during sympathetic surge → dangerous in Ketamine No significant anticonvulsant effect; mild proconvulsant Moderate (emergence reactions in ECT setting are problematic) Not generally preferred; ↑ BP during sympathetic surge → dangerous in cardiac patients; emergence reactions unpleasant; may be considered if all other agents fail to produce adequate seizure Muscle relaxant for ECT Succinylcholine 0.5–1 mg/kg (standard — complete paralysis within 60s; prevents injury from motor convulsions; allows monitoring of seizure via unparalysed forearm — inflate BP cuff BEFORE succinylcholine to isolate distal motor activity → visible in isolated unparalysed limb = ""modified cuff technique""); mivacurium or rocuronium (+ sugammadex) for pseudocholinesterase deficiency C. Special Considerations and Contraindications 2 marks Absolute contraindications: raised intracranial pressure (↑ ICP during seizure → herniation risk); space-occupying intracranial lesion; recent MI (within 3 months — haemodynamic surge risk); recent haemorrhagic or ischaemic stroke (within 3 months) Relative contraindications: severe cardiovascular disease (manage haemodynamic surge with esmolol); aortic or cerebral aneurysm (↑ rupture risk from BP surge — discuss with MDT); unstable spinal fractures; retinal detachment; recent bowel or bladder surgery (↑ intragastric pressure); severe osteoporosis (fracture risk from convulsions — ensure adequate NMB); pacemakers (ECT stimulus may interfere — use pacemaker-proof ECT machine or reprogram pacemaker to asynchronous mode before ECT) Drug interactions: lithium (↑ seizure duration and confusion — hold lithium night before ECT; ECT + lithium combination may cause prolonged seizures); monoamine oxidase inhibitors (MAOIs) — ECT + MAOIs → hypertensive crisis; generally stop MAOIs 2 weeks before ECT; benzodiazepines and anticonvulsants (↑ seizure threshold → shorten seizure duration → reduce ECT effectiveness; consider tapering dose before ECT treatment course) ★ Examiner's Pearl ECT autonomic sequence: initial vagal phase (bradycardia) → massive sympathetic surge (↑ HR 25%, ↑ MAP 30–50%) → post-ictal parasympathetic rebound. Haemodynamic surge management: esmolol 1–2 mg/kg IV 2 min before stimulus (preferred — ultra-short β₁ blocker). Best agent for ECT: methohexitone (least anticonvulsant effect → longest seizure); propofol ↓ seizure duration 30–50% (significant anticonvulsant → second-line). ECT NMB: succinylcholine 0.5–1 mg/kg + modified cuff technique. Lithium: hold night before (↑ seizure duration and confusion). References: Fink M. Convulsive therapy — a review of the first 55 years. J Affect Disord 2001;63:1-15. Avramov MN et al. Effects of methohexitone, propofol, and etomidate on seizure duration and recovery (Anesth Analg 1995;81:596-602). NICE guidelines: Electroconvulsive Therapy (ECT) — TA59. Miller RD et al. Miller's Anaesthesia, 9th Ed."

"of accidental hypothermia in the emergency setting [3] (c) Targeted temperature management (TTM) after cardiac arrest — evidence and current protocol [3]. A. Classification and Physiological Effects of Hypothermia 4 marks ⚙ Core Concept Hypothermia (core temperature <35°C) is classified by severity. Its physiological effects are multiorgan and profoundly affect anaesthetic drug requirements, coagulation, cardiac rhythm, and metabolic function. Perioperative hypothermia is common, preventable, and associated with significant morbidity. Conversely, therapeutic hypothermia exploits the cerebral and cardiac protective effects of cooling after cardiac arrest. (Sessler DI — perioperative hypothermia; Hypothermia After Cardiac Arrest Study Group HACA trial; TTM2 trial; Miller's Anaesthesia 9th Ed) Classification Core Temperature Clinical State Mild 32–35°C Shivering, tachycardia, hypertension, ↑ metabolic rate (compensating), confusion, dysarthria Moderate 28–32°C Shivering ceases (thermoregulation overwhelmed), bradycardia, ↓ CO, hypotension, AF, altered consciousness, paradoxical undressing Severe <28°C VF (highly likely <28°C), cardiac arrest, coma, no reflexes, fixed dilated pupils (may mimic death) Profound <20°C Complete cardiac arrest, isoelectric EEG, complete metabolic suppression Organ System Effect of Hypothermia Anaesthetic Relevance Cardiovascular ↓ HR; ↑ PR, QRS, QT intervals; J-wave (Osborn wave) on ECG at <30°C; AF at <32°C; VF at <28°C; ↓ CO; vasoconstriction (mild hypothermia) → ↑ SVR → ↑ BP initially; then vasodilation + ↓ CO at severe hypothermia Arrhythmias resistant to drugs at <30°C (drugs ineffective until rewarmed); DC cardioversion preferred; do NOT give repeated antiarrhythmic doses; VF at <28°C → CPR + rewarm to >30°C before expecting ROSC Respiratory ↓ RR; ↓ tidal volume; ↑ PaCO₂ (at 37°C correction); shift of ODC LEFT (↑ Hb affinity for O₂ → ↓ O₂ release to tissues); bronchospasm; loss of airway protective reflexes (aspiration risk) Apparent PaCO₂ may be misleading if not temperature-corrected; maintain normocarbia (at actual body temperature — alpha-stat vs pH- stat management on CPB) Neurological ↓ CMRO₂ (6–7% per 1°C reduction — protective); ↓ CBF; loss of consciousness at ~32°C; isoelectric EEG at <20°C; ""cold narcosis"" Reduced anaesthetic requirements (MAC reduced 5% per °C fall); propofol/opioid dose reduction needed; may not need anaesthesia at severe hypothermia Coagulation Enzyme-dependent coagulation cascade slowed (reaction rates ↓ with ↓ T); platelet dysfunction (sequestration + ↓ activation); coagulopathy worsened by acidosis (lethal triad: hypothermia + acidosis + coagulopathy in trauma) TEG/ROTEM: run at 37°C (not body temperature) → may underestimate coagulopathy; give FFP, cryoprecipitate; correct hypothermia itself is the most effective coagulopathy treatment Pharmacological ↓ Hepatic metabolism (↓ enzymatic activity) → ↑ drug half-lives (propofol, opioids, NMBDs); ↓ renal elimination; ↑ protein binding for some drugs → ↓ free drug fraction; NMB onset longer, recovery prolonged (at hypothermia) Reduce drug doses by 20–30% per 3°C below 37°C; prolonged NMB effect → delayed extubation; careful titration B. Management of Accidental Hypothermia 3 marks ""No one is dead until warm and dead"" — core principle: VF in severe hypothermia may be refractory to defibrillation until core temperature >30°C; apparent death must be confirmed only after full rewarming to >32–35°C (unless obviously fatal injury or prolonged warm cardiac arrest) Mild hypothermia (32–35°C): passive external rewarming (warm environment, insulation); active external rewarming (warmed blankets, forced-air warming — Bair Hugger, radiant heat); warm IV fluids (40–42°C); warm humidified O₂; monitor core temperature (rectal/oesophageal thermometer — oral/tympanic unreliable); rate of rewarming 0.5–2°C/hour Moderate-severe hypothermia (<32°C) with pulse: active external rewarming in ICU; warm humidified O₂ (via mask or ETT); warm IV fluids; warmed bladder irrigation; warmed pleural/peritoneal lavage if other methods failing; avoid muscle exertion (↑ O₂ demand); gentle patient handling (VF triggered by movement at <32°C); continuous cardiac monitoring; magnesium 2 g IV (raises VF threshold, reduces VF at <30°C) Severe hypothermia (<28°C) with cardiac arrest: continuous CPR (2:15 compression:ventilation at severe hypothermia — lower rate acceptable as CO₂ production ↓); do NOT give drugs until temperature >30°C (drugs accumulate + ineffective in cold); defibrillation: one shock attempt — if no ROSC, defer further shocks until >30°C; ECMO/ECLS (extracorporeal life support/ECPR) is the definitive rewarming technique for cardiac arrest with severe hypothermia — provides 4–6°C/hour rewarming + cardiac support; the highest-profile survival reports in severe hypothermic arrest involve ECMO rewarming; core rewarming takes priority over limb rewarming (prevent afterdrop — peripheral vasodilation during rewarm flushes cold acidotic blood to the core → transient further drop in core temperature) C. Targeted Temperature Management (TTM) After Cardiac Arrest 3 marks Rationale: post-cardiac arrest brain injury (PCABI) is the leading cause of death in successfully resuscitated patients; cerebral reperfusion injury occurs in the minutes-hours after ROSC (reactive oxygen species, excitotoxicity, apoptotic cascades, mitochondrial dysfunction, cerebral oedema); hypothermia → ↓ CMRO₂ (6–7%/°C) + ↓ excitatory neurotransmitter release + ↓ ROS production + ↓ inflammatory cascade → neuroprotection HACA trial (NEJM 2002) and Bernard trial (NEJM 2002): seminal trials; mild therapeutic hypothermia to 32–34°C for 12–24h after OHCA (out-of-hospital cardiac arrest) with VF → ↑ survival and ↑ neurological recovery; generated global adoption of post-arrest therapeutic hypothermia (TH) TTM trial (Nielsen et al., NEJM 2013): targeted temperature 33°C vs 36°C after OHCA → NO DIFFERENCE in mortality or neurological outcome; conclusion: preventing fever (hyperthermia) after cardiac arrest may be as important as active cooling; this shifted practice toward ""TTM"" (avoiding fever = target ≤36°C) rather than mandatory cooling to 33°C TTM2 trial (Dankiewicz et al., NEJM 2021): hypothermia 33°C vs normothermia (avoid fever ≤37.8°C) after OHCA → NO DIFFERENCE in all-cause mortality at 6 months (primary endpoint); hypothermia 33°C associated with ↑ arrhythmias; current 2023 ILCOR/ERC recommendations: maintain normothermia (36– 37.5°C) and actively prevent fever for at least 72h after cardiac arrest; routine active cooling to 33°C is no longer recommended for unselected OHCA patients based on TTM2 Current TTM protocol (post-TTM2): maintain core temperature 36–37.5°C; use surface or intravascular cooling devices to prevent fever; targeted temperature monitoring (oesophageal or rectal thermometer — not peripheral); target for at least 72 hours; patients who remain in cardiac arrest after ROSC despite adequate haemodynamics: consider 33°C cooling while awaiting further evidence ★ Examiner's Pearl Hypothermia classification: mild 32–35°C (shivering); moderate 28–32°C (shivering ceases, AF); severe <28°C (VF, cardiac arrest). J-wave (Osborn wave): pathognomonic ECG finding at <30°C. ""No one is dead until warm and dead."" Drugs ineffective <30°C — defer; one defibrillation attempt then ECMO rewarming. TTM evolution: HACA 2002 (33°C beneficial) → TTM 2013 (33°C = 36°C) → TTM2 2021 (normothermia = 33°C, ↑ arrhythmias with 33°C); current: prevent fever ≤37.8°C × 72h. References: HACA Study Group. Mild therapeutic hypothermia to improve neurological outcome (NEJM 2002;346:549-556). Nielsen N et al. TTM trial (NEJM 2013;369:197-206). Dankiewicz J et al. TTM2 trial (NEJM 2021;384:2321-2333). Sessler DI. Perioperative thermoregulation (Anesthesiology 1997;87:988-1002). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"abnormalities in cirrhosis and their perioperative management [4]. Outline the anaesthetic implications of hepatic encephalopathy [3]. ⚙ Core Concept Chronic liver disease presents the anaesthesiologist with a unique constellation of challenges — a seemingly ""normal"" PT/INR does not mean the liver is producing adequate haemostatic proteins (it also makes anticoagulant proteins — a ""rebalanced"" but fragile haemostasis); severe portopulmonary hypertension may preclude surgery; and encephalopathy creates profound neuropharmacological sensitivity. (Pugh RN — Child-Pugh score; Kamath PS — MELD; Gines P — cirrhosis complications; Miller's Anaesthesia 9th Ed) A. Child-Pugh and MELD Scoring 3 marks Parameter Child-Pugh Score (1 point) Child-Pugh Score (2 points) Child-Pugh Score (3 points) Bilirubin (μmol/L) <34 34–51 >51 Albumin (g/L) >35 28–35 <28 PT prolongation (seconds) <4 4–6 >6 Ascites None Mild (controlled) Moderate/severe (refractory) Encephalopathy None Grade I–II Grade III–IV Class Total Score 1-Year Survival Perioperative Mortality (major surgery) Class A (well-compensated) 5–6 95% 2–10% Class B (significant dysfunction) 7–9 75% 10–30% Class C (decompensated) 10–15 45–50% 50–82% MELD score (Model for End-stage Liver Disease): MELD = 9.57 × ln(creatinine) + 3.78 × ln(bilirubin) + 11.2 × ln(INR) + 6.43; range 6–40; higher = worse prognosis; MELD >15 → 30-day perioperative mortality >15%; MELD >20 → elective surgery generally contraindicated; used for liver transplant priority listing; MELD-Na incorporates sodium concentration (more accurate predictor); more accurate than Child-Pugh for prognosis because it uses continuous variables and accounts for renal function B. Coagulation Abnormalities in Cirrhosis 4 marks The ""rebalanced haemostasis"" concept: the liver produces BOTH procoagulant factors (I, II, V, VII, VIII [endothelium], IX, X, XI, XIII, fibrinogen) AND anticoagulant proteins (protein C, protein S, antithrombin III); in cirrhosis, BOTH are reduced; PT and INR are prolonged because they only test procoagulant factors (measured by the extrinsic pathway test); PT/INR does NOT accurately reflect overall haemostatic capacity in cirrhosis because the ANTICOAGULANT proteins are equally reduced (the system is rebalanced); therefore: a prolonged INR in cirrhosis does NOT necessarily indicate a bleeding tendency — the patient may have near-normal clot formation when both arms of haemostasis are tested (thromboelastography reflects this better) Specific abnormalities: ↓ Synthesis of all clotting factors except Factor VIII (VIII is from endothelium + acute phase reactant → ↑ in cirrhosis) ↓ Fibrinogen (hypofibrinogenaemia) + dysfibrinogenaemia (abnormal fibrinogen structure) Thrombocytopenia (sequestration in enlarged spleen — hypersplenism + ↓ thrombopoietin production by liver) Platelet dysfunction (↑ nitric oxide + prostacyclin from endothelium → ↓ platelet activation) Hyperfibrinolysis (↓ α₂-antiplasmin, ↓ PAI-1 synthesis → ↑ fibrinolytic activity) Disseminated intravascular coagulation (DIC) in decompensated cirrhosis (low-grade chronic DIC) Perioperative management of coagulopathy in cirrhosis: avoid unnecessary FFP transfusion solely to correct INR — it does not improve haemostasis (because anticoagulant proteins also in FFP → rebalance is maintained); give FFP if active bleeding; cryoprecipitate/fibrinogen concentrate for fibrinogen <1.5 g/L; platelets transfusion if <50×10⁹/L for surgery; vitamin K 10 mg IV (if vitamin K deficiency component — common in cholestatic disease); TEG/ROTEM to guide goal-directed transfusion; tranexamic acid for hyperfibrinolysis; desmopressin (DDAVP) 0.3 mcg/kg for platelet dysfunction (↑ release of vWF from endothelium) C. Hepatic Encephalopathy — Anaesthetic Implications 3 marks Grading (West Haven criteria): Grade I — mild confusion, altered sleep; Grade II — lethargy, asterixis (flapping tremor); Grade III — marked confusion, somnolence; Grade IV — coma, unresponsive Pathophysiology: ↑ ammonia (from gut bacterial proteolysis + impaired hepatic clearance) → astrocyte swelling → cerebral oedema; GABA-like effects of ammonia; zinc and manganese accumulation Anaesthetic implications: ↑ sensitivity to all CNS depressants (opioids, benzodiazepines, propofol) — even small doses may precipitate or worsen encephalopathy; reduce all doses by 50–70%; avoid benzodiazepines if possible Impaired drug metabolism: all hepatically metabolised drugs (most anaesthetic agents) → prolonged effect; avoid long-acting benzodiazepines (diazepam active metabolites) Avoid increases in blood ammonia perioperatively: avoid excessive protein load, constipation (give lactulose), GI bleeding (treat promptly) Post-operative encephalopathy risk: 20–30% after major surgery in cirrhotic patients; ICU admission with neurological monitoring after major surgery Drug of choice for sedation in encephalopathic patient: propofol (no active metabolites, short-acting, predictable); avoid benzodiazepines; opioid choice: fentanyl (no active metabolites — preferred); avoid morphine (accumulation) and codeine ★ Examiner's Pearl Child-Pugh C (10–15): 50–82% perioperative mortality for major surgery; MELD >20 = elective surgery contraindicated. ""Rebalanced haemostasis"" — INR prolonged in cirrhosis does NOT mean haemorrhagic tendency (anticoagulant proteins equally ↓); TEG better reflects true haemostatic status. Hepatic encephalopathy: ↑ sensitivity to all CNS drugs → 50–70% dose reduction; avoid benzodiazepines; fentanyl preferred opioid (no active metabolites); propofol preferred sedative. References: Pugh RN et al. Transection of oesophagus for bleeding oesophageal varices (Br J Surg 1973;60:646-649). Kamath PS et al. MELD score (Hepatology 2001;33:464-470). Gines P et al. Cirrhosis (Lancet 2004;364:1749-1761). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"goals"" for patients with severe aortic stenosis [3]. Outline the anaesthetic management for non-cardiac surgery in a patient with severe AS [4]. ⚙ Core Concept Severe aortic stenosis (AS) is the commonest valvular lesion in older patients requiring non-cardiac surgery — with a prevalence of 5% in octogenarians. The fixed outflow obstruction creates a pressure-overloaded, hypertrophied, non-compliant LV that is extremely vulnerable to: rapid HR changes (impaired diastolic filling), vasodilation (fixed SV cannot compensate), and volume overload (stiff LV → flash pulmonary oedema). (Faggiano P — AS periop risk; Nishimura RA — ACC/AHA valve guidelines; Miller's Anaesthesia 9th Ed) A. Pathophysiology of Aortic Stenosis 3 marks Aetiology: calcific degenerative AS (most common — elderly; calcium deposits on tricuspid aortic valve leaflets); bicuspid aortic valve (congenital — presents at younger age 50–60 years); rheumatic AS (developing countries) Severity classification (AVA — aortic valve area; and mean gradient): mild: AVA >1.5 cm²; moderate: 1.0–1.5 cm²; severe: AVA <1.0 cm² (or <0.6 cm²/m² indexed) + mean gradient >40 mmHg + peak velocity >4 m/s; very severe: AVA <0.6 cm² or mean gradient >60 mmHg Pathophysiological sequence: calcified aortic valve → fixed obstruction to LV outflow → LV must generate markedly ↑ systolic pressure to eject across the stenotic valve → LV systolic pressure may reach 200–300 mmHg (vs aortic 120 mmHg) → chronic pressure overload → concentric LVH (↑ wall thickness — the Laplace compensation: ↑ thickness reduces wall stress: σ = Pr/2h) → consequences of LVH: ↓ LV compliance (stiff ventricle) → diastolic dysfunction → relies heavily on atrial contraction (""atrial kick"") for ventricular filling; loss of atrial kick (AF) → ↓ CO by 20–40% acutely Subendocardial ischaemia — even with normal coronary arteries: ↑↑ LV wall stress + ↑↑ O₂ demand (hypertrophied muscle) + ↓ coronary perfusion (↓ diastolic time, ↓ coronary driving pressure due to ↑ LVEDP compressing subendocardial vessels) Fixed stroke volume: the hypertrophied, stiff LV ejects a relatively fixed SV regardless of preload (non-responsive to Frank-Starling); CO = SV × HR → CO becomes HR-dependent Classic triad of severe AS symptoms (and their prognostic significance): Angina (survival 5 years without intervention); Syncope (survival 3 years — occurs when vasodilation during exercise is not compensated by ↑ CO → cerebral hypoperfusion); Heart failure (survival 1–2 years) B. Haemodynamic Goals for Severe AS 3 marks ⭐ Mnemonic — SSSR for Severe AS S inus rhythm (MAINTAIN) | S low HR (50–80 bpm) | S VR maintained (AVOID vasodilation) | R easonable preload (maintain — diastolic filling critical) Parameter Goal Reason Heart rate 50–80 bpm (SLOW — avoid tachycardia) ↑ HR → ↓ diastolic filling time → ↓ LVEDV → ↓ SV → ↓ CO in the stiff hypertrophied LV; also → ↓ coronary perfusion time → subendocardial ischaemia; tachycardia is THE most dangerous haemodynamic perturbation in severe AS; avoid atropine, ketamine, atracurium (histamine → tachycardia) Rhythm Sinus rhythm (MAINTAIN) Atrial kick provides 20–40% of LV filling in the stiff, non-compliant LV; AF → sudden loss of atrial kick → acute decompensation; AF should be treated urgently with cardioversion if haemodynamically compromised SVR MAINTAIN normal to slightly ↑ (avoid vasodilation) Fixed SV → CO = SV × HR; if SVR falls → MAP falls → diastolic BP falls → coronary perfusion falls → ischaemia → further ↓ SV; the LV cannot compensate for vasodilation by ↑ CO (fixed outflow obstruction + stiff ventricle); phenylephrine (pure α₁ — ↑ SVR without tachycardia) is the vasopressor of choice Preload MAINTAIN (avoid hypovolaemia) The stiff LV requires adequate filling (higher LVEDP) for adequate SV; hypovolaemia → ↓ SV → ↓ CO → hypotension cascade; BUT avoid fluid overload → ↑ LVEDP above 25 mmHg → ↑ LA pressure → pulmonary oedema (the stiff LV has very steep EDPVR — small ↑ in volume → large ↑ in pressure) Contractility MAINTAIN (avoid myocardial depression) The hypertrophied LV has limited contractile reserve; myocardial depressants (propofol, volatile agents at >1 MAC, thiopentone) → ↓ already compensated contractility → acute decompensation; titrate carefully C. Anaesthetic Management for Non-Cardiac Surgery 4 marks Pre-operative assessment: confirm severity (echo: AVA, mean gradient, LVEF); look for new symptoms (progression to symptomatic AS greatly ↑ perioperative risk); cardiology referral; consider TAVR (transcatheter aortic valve replacement) or SAVR before elective major non-cardiac surgery if AVA <1.0 cm² AND symptoms present (ACC/AHA Class I recommendation); if truly urgent non-cardiac surgery → proceed with careful haemodynamic management; discuss risk explicitly with patient and surgical team; elective surgery in asymptomatic AS with preserved LVEF: perioperative risk is acceptable (3–4%) if haemodynamic goals are maintained — discuss with cardiologist Monitoring: invasive arterial line (beat-to-beat BP — essential; even minor hypotension must be detected and treated immediately before ischaemic cascade begins); central venous line; TOE (transoesophageal echocardiography) intraoperatively if major surgery — monitors preload, wall motion abnormalities, valve gradients, ventricular function; consider pulmonary artery catheter or LiDCO/FloTrac for continuous CO monitoring Induction technique: SLOW and CAREFULLY TITRATED; avoid propofol bolus (sudden ↓ SVR + ↓ contractility → catastrophic hypotension); options: etomidate (most cardiovascularly stable — minimal SVR/contractility depression); if propofol: use very slowly (0.5–1 mg/kg over 5–10 min), titrated; thiopentone: acceptable in low doses; avoid ketamine (tachycardia); GA preferred over high-level neuraxial (epidural/spinal → ↓ SVR → ↓ MAP → ischaemic cascade); if spinal is required (e.g., hip replacement): low-dose hypobaric or isobaric bupivacaine, careful titration, phenylephrine infusion ready Maintenance: volatile agent at ≤0.5–1 MAC (↓ SVR + ↓ contractility at higher concentrations); TIVA with propofol (careful titration) + remifentanil; avoid tachycardia (beta-blockade if HR >80 — esmolol 10–25 mg IV); vasopressor of choice: phenylephrine 50–100 mcg boluses or infusion (↑ SVR without tachycardia); avoid atropine for bradycardia (phenylephrine + ↑ preload preferable); ↑ preload with IV fluid bolus if MAP falls; normocarbia; avoid acidosis ★ Examiner's Pearl Severe AS: AVA <1.0 cm², mean gradient >40 mmHg, peak velocity >4 m/s. Classic triad: angina (5yr survival), syncope (3yr), heart failure (1–2yr). Haemodynamic goals SSSR: Sinus rhythm + Slow HR (50–80) + SVR maintained + Reasonable preload. Vasopressor of choice: phenylephrine (pure α₁ — ↑ SVR, no tachycardia). Avoid: propofol bolus (↓ SVR + ↓ contractility), spinal (sudden ↓ SVR), tachycardia, atropine, hypotension. References: Nishimura RA et al. ACC/AHA Valve Guideline 2014 update (J Am Coll Cardiol 2014;63:e57-185). Faggiano P et al. Aortic valve stenosis in patients undergoing non-cardiac surgery (Eur J Anaesthesiol 2012;29:1-8). Miller RD et al. Miller's Anaesthesia, 9th Ed, Chapter 67."

"implications — NMB sensitivity, drug interactions and choice of agents [4] (c) Myasthenic crisis vs cholinergic crisis — distinction and management [3]. ⚙ Core Concept Myasthenia gravis (MG) is the prototypic neuromuscular junction disorder — an autoimmune attack on the post-synaptic nAChR reduces functional receptor numbers → fatigable weakness. It creates extreme sensitivity to NDMBs, relative resistance to succinylcholine, and the potential for post-operative myasthenic crisis. Understanding the difference between myasthenic crisis and cholinergic crisis is a classic exam favourite. (Vincent A — MG pathophysiology; Baraka A — NMB in MG; Miller's Anaesthesia 9th Ed) A. Pathophysiology and Classification 3 marks Autoimmune mechanism: in 85% of generalised MG: autoantibodies (IgG) against nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction → antibody binding → complement-mediated receptor destruction + receptor crosslinking and internalisation + blockade of ACh binding site → ↓ functional nAChR number (by 70–90% in severe MG) → ACh released normally but fewer receptors available → impaired EPP (end-plate potential) → fails to reach threshold → action potential fails to propagate → no muscle contraction; the key hallmark: fatigable weakness (worsens with repeated effort as ACh depletes transiently — partial receptor blockade means marginal safety factor) Other antibodies: 10% anti-MuSK (muscle-specific kinase — anchors nAChRs at NMJ); 5% anti-LRP4; 5% seronegative Osserman Classification: Class I — ocular only (ptosis, diplopia); Class IIa — mild generalised; Class IIb — moderate generalised; Class III — acute severe (respiratory involvement); Class IV — chronic severe; Class V — intubated (crisis) Thymoma association: 10–15% of MG patients have thymoma (thymectomy → sustained remission in 25–30%; improvement in 50–60%); all patients with generalised MG should have CT chest to exclude thymoma B. Anaesthetic Implications 4 marks Agent / Consideration Effect in MG Recommendation NDMBs (rocuronium, vecuronium, atracurium) EXTREME sensitivity — profound block at 5–10% of normal dose; even standard ""intubation"" doses produce complete block lasting 4– 8× normal duration; the ↓ nAChR numbers → less receptors to be blocked → near-complete block with tiny doses If NDMB is essential: use 10–20% of normal intubating dose and titrate with TOF monitoring; cisatracurium/atracurium preferred (organ- independent elimination); have sugammadex available for emergency reversal of rocuronium; volatile or LA technique preferred to avoid NMBs entirely Succinylcholine RELATIVE RESISTANCE — requires LARGER than normal dose; the ↓ nAChR numbers means more drug needed to achieve adequate depolarisation for block; ED₉₅ approximately doubled If RSI required: succinylcholine 2 mg/kg (double normal dose); paradoxical response — may cause prolonged phase II block in MG patients on pyridostigmine (anticholinesterase → ↓ plasma cholinesterase → delayed succinylcholine hydrolysis); use with caution Pyridostigmine (anticholinesterase treatment) Inhibits all AChE (NMJ, plasma esterase) → ↓ plasma cholinesterase → prolongs succinylcholine; ↑ NMJ ACh → may partially restore NMJ function; CONTINUE perioperatively (stopping → ↑ weakness; but some anaesthetists hold morning dose to reduce secretions) CONTINUE pyridostigmine perioperatively; if held: restart IV equivalent dose ASAP; monitor for cholinergic effects (excessive secretions, bradycardia) Volatile anaesthetics ↓ Post-synaptic nAChR function (at NMJ) + direct muscle relaxant effect → potentiate NMJ block in MG; sevoflurane produces significant NMJ blockade at ≥1 MAC in MG patients Use lower concentrations (0.5–0.8 MAC); supplement with IV agents; consider TIVA with propofol + remifentanil + LA techniques to avoid volatile-induced NMJ depression Extubation criteria (critical in MG) MG patients have ↓ respiratory reserve; post-operative respiratory failure → myasthenic crisis common (20–30% after thymectomy); TOF ratio ≥0.9 is NOT sufficient alone in MG Extubate only when: (1) TOF ratio ≥0.9; (2) VC ≥15 mL/kg; (3) sustained head lift ≥5 sec; (4) MIP (maximal inspiratory pressure) >-20 cmH₂O; (5) patient fully alert; plan ICU admission after thymectomy or major surgery C. Myasthenic Crisis vs Cholinergic Crisis 3 marks Feature Myasthenic Crisis Cholinergic Crisis Cause Insufficient ACh effect at NMJ — disease deterioration, infection, surgery, stress, inadequate pyridostigmine Excess ACh — overdose of anticholinesterase (pyridostigmine overdose or too frequent dosing) Weakness pattern Fatigable weakness — gets worse with activity; ptosis, dysphagia, dysarthria, respiratory weakness Weakness that is CONSTANT (not fatigable) — muscle depolarisation block from excess ACh Pupils Normal or slightly dilated MIOSIS (pinpoint — muscarinic effect of excess ACh) Secretions Dry mouth (insufficient cholinergic tone) SALIVATION, lacrimation, rhinorrhoea, bronchospasm, diarrhoea (muscarinic excess — DUMBELS: Diarrhoea, Urination, Miosis, Bradycardia, Emesis, Lacrimation, Salivation) Edrophonium IMPROVES weakness (↑ NMJ ACh → improves transmission) WORSENS weakness (further ↑ ACh → further depolarisation test (Tensilon test) block → more weakness); fasciculations worsen Management Secure airway (intubation/ICU); IVIG 2 g/kg over 5 days OR plasma exchange (PE) × 5 sessions (removes autoantibodies); ↑ pyridostigmine dose; immunosuppression; treat precipitant (infection → antibiotics); steroids long-term (prednisolone) STOP pyridostigmine; atropine for muscarinic symptoms; ICU support; airway management; allow AChE to recover over hours; resume pyridostigmine at lower dose when recovered ★ Examiner's Pearl MG mechanism: IgG anti-nAChR antibodies → receptor destruction → ↓ functional receptors → fatigable weakness; nAChR reduced by 70–90% in severe MG. NDMBs: EXTREME sensitivity (use 10–20% of normal dose). Succinylcholine: relative resistance (need 2 mg/kg). Myasthenic crisis vs cholinergic crisis: edrophonium IMPROVES myasthenic (↑ ACh effect at depleted receptors), WORSENS cholinergic (further excess ACh). Miosis = cholinergic crisis (DUMBELS). Treatment: IVIG or plasma exchange (remove autoantibodies). References: Vincent A et al. Myasthenia gravis (Lancet 2001;357:2122-2128). Baraka A. Anaesthesia and critical care of myasthenia gravis (Middle East J Anaesthesiol 1992;11:415-447). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"and optimisation [3]. Discuss intraoperative ventilation strategy and postoperative pulmonary complication prevention [4]. ⚙ Core Concept COPD (FEV₁/FVC <0.70 post-bronchodilator) affects 10–15% of adult surgical patients — pulmonary complications are the most common cause of prolonged hospital stay after major surgery. Pre-operative optimisation, careful ventilation strategy, and targeted post-operative respiratory support are the pillars of COPD perioperative management. (GOLD 2023 guidelines; Arozullah AM — pulmonary risk index; Miller's Anaesthesia 9th Ed) A. Spirometric Patterns and GOLD Classification 3 marks Obstructive pattern: FEV₁/FVC <0.70 (post-bronchodilator confirms obstruction); ↓ FEV₁ (flow-limited expiration from airway collapse); FVC may be normal or ↓; air trapping → ↑ RV; hyperinflation → ↑ TLC; diffusion capacity (DLCO) ↓ in emphysema (alveolar surface area ↓) GOLD Stage FEV₁ (% predicted) Symptoms Perioperative Risk GOLD 1 (Mild) ≥80% Chronic cough, sputum — often absent Low GOLD 2 (Moderate) 50–79% Dyspnoea on exertion, ↑ exacerbations Moderate GOLD 3 (Severe) 30–49% Significant dyspnoea, frequent exacerbations High GOLD 4 (Very severe) <30% Severe dyspnoea at rest, respiratory failure, cor pulmonale Very high — consider deferral B. Perioperative Assessment and Optimisation 3 marks Assessment: spirometry (FEV₁, FVC, FEV₁/FVC, DLCO); ABG (chronic CO₂ retention — PaCO₂ >6 kPa = ↑ risk; renal compensation of respiratory acidosis); CXR (hyperinflation, bullae — risk of pneumothorax with positive pressure ventilation); echocardiography (pulmonary hypertension, RV function — cor pulmonale); exercise tolerance (6-minute walk test, CPET); Arozullah pulmonary risk index (identifies high-risk patients) Optimisation (minimum 6–8 weeks before elective surgery): smoking cessation (at least 8 weeks — less than this does not ↓ secretions, may transiently ↑ secretions); optimise bronchodilators (LABA + LAMA + ICS per GOLD guidelines — ensure inhaler technique correct); treat exacerbation with antibiotics + oral steroids if indicated; chest physiotherapy to clear secretions; treat cor pulmonale (diuretics); CPAP or NIV for OHS component; outpatient pulmonary rehabilitation (6 weeks → ↑ FEV₁, ↑ exercise tolerance, ↑ QoL) C. Intraoperative Ventilation and Post-operative Prevention 4 marks Intraoperative ventilation strategy: avoid high-pressure ventilation (dynamic hyperinflation — ""breath stacking"" — already compromised compliance + air trapping → auto-PEEP → cardiovascular collapse); settings: low RR (10–12/min), prolonged expiratory time (I:E ratio 1:3 to 1:4 — allows complete exhalation before next breath); TV 6–8 mL/kg IBW; low PEEP (auto-PEEP from gas trapping may exceed set PEEP — disconnect airway briefly before PEEP adjustment to measure intrinsic PEEP); monitor capnography carefully (dead space ↑ → ETCO₂ may underestimate PaCO₂ significantly — check ABG periodically); regional anaesthesia avoids GA-related complications where feasible (thoracic epidural for thoracotomy; spinal for lower limb) Post-operative pulmonary complication prevention (ARISCAT score — risk stratification): lung recruitment manoeuvres; low tidal volume ventilation; early extubation (prolong intubation → VAP → worse outcomes); chest physiotherapy; early mobilisation; adequate analgesia (multimodal — thoracic epidural/PVB reduces splinting → ↓ atelectasis); NIV/CPAP early if SpO₂ <94% on O₂; targeted O₂ delivery (SpO₂ 88–92% in chronic CO₂ retainers — higher O₂ → suppresses hypoxic drive → ↑ CO₂ retention → hypercapnic encephalopathy); incentive spirometry ★ Examiner's Pearl COPD spirometry: FEV₁/FVC <0.70 (post-bronchodilator); GOLD 4: FEV₁ <30% → very high perioperative risk. Intraoperative: low RR, prolonged expiratory time (I:E 1:3 to 1:4) to prevent air trapping and auto-PEEP. Oxygen target in chronic CO₂ retainer: SpO₂ 88–92% (not 98–100% — hypoxic drive suppression → ↑ CO₂ retention). Smoking cessation: minimum 8 weeks before elective surgery. References: GOLD (Global Initiative for Chronic Obstructive Lung Disease). Global Strategy for Diagnosis, Management, and Prevention of COPD, 2023. Arozullah AM et al. Multifactorial risk index for predicting postoperative respiratory failure (Ann Surg 2000;232:242-253)."

"management [4] (b) Hypothyroid coma — clinical features and anaesthetic management [3] (c) Anaesthetic considerations for thyroid surgery including airway management [3]. ⚙ Core Concept Thyroid disease spans a wide spectrum from subclinical abnormalities (common — 5–10% of population) to life-threatening crises. Thyroid storm and hypothyroid coma are both anaesthetic emergencies. Thyroid surgery presents unique airway challenges — compression, displacement, and post- operative haematoma. (Burch HB, Wartofsky L — thyroid storm score; Ringel MD; Miller's Anaesthesia 9th Ed) A. Thyroid Storm — Precipitants, Features and Management 4 marks Precipitants: surgery or trauma (especially on the thyroid itself — not rendering patient euthyroid before surgery); infections (most common); radioactive iodine (transient thyrotoxicosis from radiation thyroiditis); contrast media; parturition; non-compliance with antithyroid drugs; amiodarone (40% iodine by weight) Burch-Wartofsky Point Scale (>45 points = likely thyroid storm): temperature (scored 0–15 points based on severity of hyperthermia); CNS effects (mild agitation 10, delirium/psychosis 20, coma 30); GI/hepatic dysfunction (diarrhoea/nausea/vomiting 10, jaundice 20); cardiovascular (HR, AF, cardiac failure — up to 45 points from HR component alone); precipitant identified (10 points) Management (remember ""BATHED""): B eta-blockers: propranolol 60–80 mg PO q4h (or esmolol infusion IV if PO not possible) — controls tachycardia and peripheral T4→T3 conversion; symptomatic control A ntithyroid drugs: propylthiouracil (PTU) 500–1000 mg loading then 250 mg q4h (preferred — also blocks T4→T3 peripheral conversion) OR methimazole 60–80 mg/day; blocks new hormone synthesis T hionamide THEN iodine (Lugol's iodine 8 drops q6h): MUST give antithyroid drug first (at least 1 hour before iodine) — iodine initially provides substrate for new hormone synthesis if given without antithyroid drug (""Jod-Basedow"" effect); after 1h: Lugol's iodine blocks hormone release (Wolff-Chaikoff effect) H ydrocortisone 100 mg IV q8h: blocks T4→T3 conversion; covers relative adrenal insufficiency (thyroid storm depletes adrenal reserves); anti- inflammatory E xpressive cooling: paracetamol (NOT aspirin — displaces T4 from binding proteins → ↑ free T4); ice packs; cooling blanket; target temperature <38.5°C D efeat the cause: treat precipitant (antibiotics if infection; manage surgical complication) B. Hypothyroid Coma 3 marks Clinical features: progressive drowsiness → coma; hypothermia; bradycardia; ↓ BP; hyponatraemia (SIADH); hypoglycaemia; hypoventilation (hypercapnia — hypoventilation from ↓ respiratory drive); delayed deep tendon reflexes (""hung-up reflexes""); myxoedema facies; non-pitting oedema; periorbital oedema; ↑ CK; macroglossia (airway risk); myopericardial effusion Anaesthetic management: extreme sensitivity to all CNS depressants and opioids (↓ elimination, ↑ pharmacodynamic sensitivity) → use 25–50% of normal doses; hypothermia → ↓ MAC, ↓ drug requirements; hyponatraemia (Na ⁺ <120) → seizure risk → correct slowly (hypertonic saline if symptomatic, no faster than 0.5–1 mEq/L/hour); airway: macroglossia + myxoedema tissues → difficult airway — have videolaryngoscope and surgical airway kit immediately available; treatment: levothyroxine 200–500 mcg IV loading (cautiously — rapid correction in cardiac disease may precipitate MI); hydrocortisone 100 mg IV (adrenal insufficiency frequently co-exists); active rewarming; HDU/ICU admission C. Anaesthetic Considerations for Thyroid Surgery 3 marks Airway assessment: CT neck/thorax — assess tracheal deviation and compression (intrathoracic goitre); assess tracheal calibre at narrowest point; if tracheal compression >50% → awake fibreoptic intubation; if tracheal softening (tracheomalacia from longstanding compression) → post-operative airway collapse risk even after tumour removal Induction and intubation: videolaryngoscopy or awake FOI for anticipated difficult airway; reinforced (armoured/spiral wire) ETT (to prevent kinking from surgical manipulation); intraoperative neuromonitoring of recurrent laryngeal nerve (RLN) — avoid NMBs or use TOF-guided ultra-light NMB to allow NMM monitoring; tube position may be intermittently assessed by laryngeal EMG Post-operative haematoma (the most feared complication): occurs in 1–2% within 6h of surgery; sudden neck swelling + stridor + dyspnoea → immediately release skin sutures at bedside (or bring patient back to theatre) — this relieves the haematoma pressure and may restore airway; have surgical team immediately available during the first 6h; if airway compromised → attempt laryngoscopy (oedema may prevent view) → consider awake tracheostomy if cannot intubate; have CICO equipment immediately at the bedside in recovery ★ Examiner's Pearl Thyroid storm treatment BATHED: Beta-blocker → Antithyroid → Thionamide then iodine (1h gap — Jod-Basedow risk) → Hydrocortisone → Expressive cooling → Defeat cause. Burch-Wartofsky >45 points = likely storm. Hypothyroid: extreme sensitivity to CNS depressants (25–50% dose); macroglossia → difficult airway. Thyroid haematoma: 1–2% in first 6h → release skin sutures immediately at bedside → restores airway in most cases. References: Burch HB, Wartofsky L. Life-threatening thyrotoxicosis — thyroid storm (Endocrinol Metab Clin NA 1993;22:263-277). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"haemodynamic management challenges in patients with chronic spinal cord injury [3]. What are the specific considerations for anaesthesia below, at, and above T6 injury level? [3] ⚙ Core Concept Spinal cord injury (SCI) creates a permanent physiological reorganisation — loss of descending supraspinal control results in spastic paralysis, autonomic instability, and loss of normal thermoregulation. Autonomic dysreflexia (AD) is a potentially lethal hypertensive emergency unique to patients with SCI above T6 that can be triggered by any stimulus below the injury level — including surgical incision, urinary catheter, or even a tight clothing waistband. (Karlsson AK — autonomic dysreflexia; Teasell R — SCI management; Miller's Anaesthesia 9th Ed) A. Autonomic Dysreflexia 4 marks Definition and mechanism: AD is an acute, massive, unmodulated sympathetic reflex response to a stimulus below the level of the SCI, occurring in patients with SCI at or above T6; normally, supraspinal centres modulate and limit sympathetic outflow below the injury — in SCI above T6 (above the major splanchnic sympathetic outflow at T6-T10), this modulation is lost; a noxious stimulus below the level → enters the spinal cord below the lesion → triggers sympathetic reflex via the intact spinal cord below the injury → massive sympathetic vasoconstriction below the lesion → acute severe hypertension (SBP may rise to 200– 300 mmHg); the ascending signal cannot reach the brain (blocked by the SCI) → cerebral baroreceptors detect the hypertension → activate parasympathetic response (bradycardia, vasodilatation ABOVE the injury — flushing, nasal congestion, sweating) → but this parasympathetic response cannot reach below the injury → the sympathetic vasoconstriction persists below the lesion; the result: severe hypertension + bradycardia + diaphoresis/flushing ABOVE the injury + piloerection/pallor BELOW Common triggers: bladder distension (most common — 85%) or urinary tract infection; bowel distension (faecal impaction, rectal examination); surgical incision; pressure sores; tight clothing; spasticity; DVT; labour in pregnant SCI patients (AD occurs in virtually all T6 SCI patients during uterine contractions → spinal anaesthesia is strongly recommended) Emergency management of AD episode: Sit the patient upright immediately (orthostatic ↓ BP from lower limb venous pooling — helps ↓ BP while cause is identified) Identify and remove the trigger (catheterise bladder or unblock catheter — most common; loosen tight clothing; remove any pressure; check skin) If BP remains severely elevated (SBP >150 mmHg): sublingual nifedipine 10 mg (rapid onset vasodilation — bite and swallow) OR glyceryl trinitrate (GTN) spray sublingually → rapid vasodilation; IV labetalol (combined α+β) or IV hydralazine if sublingual route inadequate; do NOT use β-blocker alone (unopposed α activation → worse hypertension) Intraoperatively: deepen anaesthesia (most effective intervention — removes surgical stimulus); regional anaesthesia (spinal or epidural) provides complete afferent block → prevents AD even in SCI patients; IV GTN or SNP infusion for refractory hypertension B. Haemodynamic Challenges in Chronic SCI 3 marks Chronic hypotension: loss of supraspinal sympathetic tone → chronic vasodilation → resting BP 90–110/60–70 mmHg (normal for that patient); supine hypertension does not apply; ""hypertension"" threshold effectively lower Orthostatic hypotension: loss of sympathetic venoconstriction → pooling in lower limbs when upright → ↓ venous return → ↓ CO; treat with compression stockings, elevation, fludrocortisone (↑ intravascular volume), midodrine (α₁ agonist) Succinylcholine contraindication: upregulated extrajunctional nAChRs → hyperkalaemia risk (same as burn/denervation patients); contraindicated after 24– 72h following acute SCI; safe only within the first 24h after acute SCI C. Anaesthetic Considerations by SCI Level 3 marks SCI Level Respiratory Impact AD Risk Key Anaesthetic Consideration Above T6 (cervical/high thoracic) Significant — diaphragm ± intercostals paralysed; may be ventilator-dependent HIGH — all surgery below injury → AD risk; spinal or epidural strongly recommended Regional anaesthesia (spinal/epidural) prevents AD afferent stimulus from reaching cord; GA: careful airway management (cervical SCI → cervical spine instability); post-op ventilatory support T6–T10 (thoracic) Intercostal muscles affected; intact diaphragm; can breathe spontaneously but ↓ cough efficacy Variable — may or may not develop AD depending on exact level Regional preferred for procedures below injury; chest physiotherapy post- op; epidural or PVB for thoracic procedures; secretion clearance important Below T10 (lumbar/sacral) Respiratory function usually preserved LOW — sympathetic outflow below T6 not involved Standard anaesthetic approach; succinylcholine contraindicated in chronic SCI regardless of level ★ Examiner's Pearl AD: SCI at/above T6 + stimulus below injury → massive sympathetic reflex → severe hypertension + bradycardia + diaphoresis/flushing above lesion. Most common trigger: bladder distension. Emergency: sit upright → remove trigger → sublingual nifedipine or GTN → IV labetalol. Intraoperative AD: DEEPEN ANAESTHESIA (most effective); regional (spinal/epidural) prevents AD completely. Succinylcholine contraindicated >24h post-SCI (upregulated extrajunctional nAChRs → hyperkalaemia). References: Karlsson AK. Autonomic dysreflexia (Spinal Cord 1999;37:383-391). Colachis SC. Autonomic hyperreflexia with spinal cord injury (J Am Paraplegia Soc 1992;15:171-186). Miller RD et al. Miller's Anaesthesia, 9th Ed."

"reactions and describe the pathophysiology and management of TRALI and TACO [4]. Summarise the SHOT reporting system and its impact on transfusion safety [3]. ⚙ Core Concept Transfusion is the most common therapeutic intervention in hospital patients — 2.3 million units of blood are transfused annually in the UK. Transfusion errors and reactions are significant causes of morbidity and mortality, yet many are preventable. The SHOT haemovigilance system provides the evidence base for transfusion safety improvements. (SHOT Annual Report 2023; Kleinman S — TRALI; AABB Technical Manual; Miller's Anaesthesia 9th Ed) A. ABO Compatibility 3 marks ABO genetics: ABO locus on chromosome 9 — three alleles: A, B, O (O is recessive); A gene → N-acetylgalactosaminyl transferase → A antigen; B gene → galactosyl transferase → B antigen; O gene → non-functional enzyme → H antigen (no A or B); antibodies: naturally occurring IgM anti-A and/or anti-B formed in the first year of life (stimulated by gut bacteria cross-reactive antigens) Blood groups and compatibility: Group O (universal donor — RBC): neither A nor B antigens; compatible with A, B, AB, and O recipients; however contains anti-A and anti-B antibodies → donated plasma may cause haemolysis in non-O recipients if given in large volumes Group AB (universal plasma donor): has both A and B antigens; no naturally occurring anti-A or anti-B; can receive RBCs from all groups; AB plasma contains no anti-A or anti-B → universal plasma donor Emergency: O-negative RBCs for unknown blood group (O Rh-negative = truly universal donor); AB-positive FFP for unknown group plasma Rhesus (D) system: Rh D antigen — most immunogenic after ABO; Rh D negative patients who receive Rh D positive blood → form anti-D IgG antibodies (immune alloimmunisation) → subsequent exposure or pregnancy → haemolytic disease of the fetus and newborn (HDFN); anti-D immunoglobulin (Rhogam) prevents sensitisation in Rh-negative women B. Transfusion Reactions — TRALI and TACO 4 marks Feature TRALI (Transfusion-Related Acute Lung Injury) TACO (Transfusion-Associated Circulatory Overload) Definition Acute lung injury occurring within 6h of transfusion; ARDS-like presentation; new bilateral pulmonary infiltrates on CXR; PaO₂/FiO₂ <300 mmHg; no evidence of cardiac failure/volume overload Cardiogenic pulmonary oedema occurring during or within 6h of transfusion; new or worsened pulmonary oedema; hypertension; tachycardia; ↑ BNP/NT-proBNP Mechanism Donor leucocyte antibodies (anti-HLA or anti-HNA in donor plasma — usually multiparous female donors) bind to recipient's neutrophils → neutrophil activation → ↑ capillary permeability → non-cardiogenic pulmonary oedema; ""two-hit model"": first hit = patient's pre- existing condition (surgery, sepsis); second hit = transfusion trigger Volume overload — transfusion volume exceeds cardiac capacity to compensate → ↑ LVEDP → ↑ LAP → hydrostatic pulmonary oedema; risk: elderly, cardiac failure, renal failure, low body weight Incidence ~1:10,000 units FFP or platelets (highest); rarer with RBCs; leading cause of transfusion- related mortality in UK (SHOT) Most common transfusion complication reported to SHOT (approximately 1:1,000 transfusions); severely underreported Management STOP transfusion; 100% O₂; mechanical ventilation if severe (lung-protective strategy — TV 6 mL/kg IBW); NO diuretics (non-cardiogenic oedema — diuretics worsen hypovolaemia without benefit); supportive care; report to blood bank and SHOT STOP or slow transfusion; diuretics (furosemide 40–80 mg IV — excellent response to diuresis unlike TRALI); sit upright; O₂; GTN if severe hypertension; haemofiltration if refractory Prevention Male-only or previously untested female plasma donations (removes anti-HLA antibodies); leucodepletion of blood products; pathogen inactivation reduces TRALI risk Single-unit transfusion strategy (transfuse one unit then reassess — do not ""routine"" 2-unit transfuse); restrict transfusion trigger (Hb <7–8 g/dL); use diuretic prophylaxis in high-risk patients (furosemide between units) C. SHOT Reporting System 3 marks SHOT (Serious Hazards of Transfusion): established 1996; confidential, anonymous, voluntary haemovigilance scheme in the UK; collects data on all significant adverse events and reactions from transfusion; annual reports identify trends, learning points, and recommendations; key findings: wrong blood in tube (WBIT) errors — patient identification failures remain the commonest avoidable transfusion error; TACO: consistently the most commonly reported reaction; TRALI: has dramatically declined since male-only plasma policy introduction (2004 UK); recommendations from SHOT have driven: electronic patient identification systems; two-person bedside checks; pre-transfusion sample identity checks Key SHOT categories: ABO incompatible transfusion (most feared — mortality ~1:2,000,000 UK); TRALI; TACO; FNHTR (febrile non-haemolytic transfusion reaction — most common acute reaction — donor leucocyte cytokines → fever/chills — not dangerous; treat with paracetamol; no need to stop transfusion if mild); allergic reactions (urticaria → diphenhydramine; anaphylaxis → see Q33); transfusion-associated graft-vs-host disease (TA-GvHD) — prevented by irradiation of cellular products in immunocompromised recipients ★ Examiner's Pearl O-negative = universal RBC donor (no A, B, D antigens); AB = universal plasma donor (no anti-A or anti-B). TRALI vs TACO: TRALI = non-cardiogenic (do NOT use diuretics); TACO = cardiogenic (diuretics excellent). TRALI mechanism: donor anti-HLA/anti-HNA antibodies → neutrophil activation → capillary leak. SHOT: WBIT = most common preventable error; TACO = most commonly reported reaction; TRALI declined after male-only plasma policy. Key distinction: TRALI → no diuretics; TACO → furosemide. References: SHOT Annual Report 2023. Kleinman S et al. TRALI: ISBT working group update (Transfusion 2019;59:374-382). Bolton-Maggs PHB. SHOT Reports. Miller RD et al. Miller's Anaesthesia, 9th Ed."